Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 60,773,436
  • Shares Outstanding, K 211,430
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.78
  • Price/Sales 5.32
  • Price/Cash Flow 12.18
  • Price/Book 5.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
268.91 +6.89%
on 06/29/17
296.95 -3.20%
on 07/26/17
+12.80 (+4.66%)
since 06/28/17
3-Month
244.28 +17.67%
on 05/31/17
296.95 -3.20%
on 07/26/17
+16.23 (+5.98%)
since 04/28/17
52-Week
244.28 +17.67%
on 05/31/17
307.33 -6.47%
on 08/02/16
+21.21 (+7.97%)
since 07/28/16

Most Recent Stories

More News
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.

ENZ : 10.98 (+0.09%)
EXEL : 27.63 (+1.92%)
ACOR : 21.70 (unch)
BIIB : 287.44 (-0.18%)
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies

Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ:...

BIIB : 287.44 (-0.18%)
Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies

Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ:...

BIIB : 287.44 (-0.18%)
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

MRK : 64.11 (+0.66%)
LLY : 83.10 (+0.10%)
VRTX : 154.15 (-1.31%)
ABBV : 70.44 (-1.80%)
AMGN : 174.54 (+1.39%)
GSK : 40.93 (+0.44%)
BIIB : 287.44 (-0.18%)
Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics

Research Desk Line-up: Biogen Post Earnings Coverage

ALPN : 9.14 (+6.90%)
NVLS : 2.40 (+2.13%)
KITE : 111.43 (+2.34%)
BIIB : 287.44 (-0.18%)
Biogen Inc Rises 4.54% on Heavy Volume: Watch For Potential Pullback

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.02 to a high of $296.00. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $291.91...

BIIB : 287.44 (-0.18%)
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

CELG : 134.10 (-0.04%)
JNJ : 131.85 (+0.78%)
MRK : 64.11 (+0.66%)
NVS : 84.75 (-0.26%)
BMY : 55.27 (+1.90%)
ALXN : 137.99 (+3.04%)
BIIB : 287.44 (-0.18%)
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

IRWD : 17.60 (+5.71%)
MDCO : 38.41 (+1.21%)
INCY : 135.74 (+2.28%)
GILD : 75.94 (+1.31%)
AMGN : 174.54 (+1.39%)
BIIB : 287.44 (-0.18%)
NKTR : 22.91 (+1.33%)
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

JNJ : 131.85 (+0.78%)
ABBV : 70.44 (-1.80%)
AMGN : 174.54 (+1.39%)
BIIB : 287.44 (-0.18%)
Estimize Roundtable: What these experts say would have been a better path to Health Care reform

This week on the Estimize Roundtable, Estimize’s CEO, Leigh Drogen, and SVP of Media, Christine Short, are joined by Joe McCann, CEO and founder of Slingshot Insights, and and Spencer Jakab, Deputy Editor...

PETS : 48.37 (-1.21%)
VRTX : 154.15 (-1.31%)
IBB : 321.82 (+0.63%)
GILD : 75.94 (+1.31%)
BIIB : 287.44 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 292.21
1st Resistance Point 289.83
Last Price 287.44
1st Support Level 284.53
2nd Support Level 281.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.